Elanco Animal Health Incorporated (NYSE:ELAN) Shares Bought by National Bank of Canada FI

National Bank of Canada FI increased its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 331.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 758,000 shares of the company's stock after buying an additional 582,355 shares during the quarter. National Bank of Canada FI owned about 0.15% of Elanco Animal Health worth $11,097,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Acadian Asset Management LLC bought a new position in shares of Elanco Animal Health in the third quarter valued at approximately $95,000. HBK Sorce Advisory LLC bought a new stake in shares of Elanco Animal Health in the 4th quarter worth $169,000. C M Bidwell & Associates Ltd. bought a new position in shares of Elanco Animal Health during the third quarter valued at about $129,000. Allspring Global Investments Holdings LLC grew its position in Elanco Animal Health by 10.2% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 12,123 shares of the company's stock worth $181,000 after purchasing an additional 1,127 shares in the last quarter. Finally, Innovis Asset Management LLC purchased a new stake in Elanco Animal Health in the 3rd quarter valued at about $144,000. Institutional investors own 97.48% of the company's stock.

Elanco Animal Health Trading Up 1.9 %

Shares of ELAN stock traded up $0.31 on Thursday, hitting $17.21. 7,407,675 shares of the company's stock traded hands, compared to its average volume of 4,585,274. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.35 and a current ratio of 2.75. The stock has a market capitalization of $8.50 billion, a price-to-earnings ratio of -6.79, a P/E/G ratio of 1.42 and a beta of 1.34. The company's fifty day simple moving average is $14.98 and its 200 day simple moving average is $14.04. Elanco Animal Health Incorporated has a one year low of $7.88 and a one year high of $17.43.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its earnings results on Wednesday, May 8th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.08. Elanco Animal Health had a positive return on equity of 6.44% and a negative net margin of 27.87%. The company had revenue of $1.21 billion during the quarter, compared to analysts' expectations of $1.18 billion. During the same period in the prior year, the business posted $0.45 EPS. Elanco Animal Health's quarterly revenue was down 4.1% compared to the same quarter last year. Equities analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Analyst Upgrades and Downgrades

ELAN has been the subject of several recent analyst reports. TheStreet raised Elanco Animal Health from a "d+" rating to a "c-" rating in a report on Friday, February 23rd. Barclays raised their target price on Elanco Animal Health from $19.00 to $23.00 and gave the company an "overweight" rating in a research report on Thursday. The Goldman Sachs Group boosted their price target on shares of Elanco Animal Health from $12.50 to $14.00 and gave the stock a "sell" rating in a report on Tuesday, February 27th. Finally, Morgan Stanley lifted their price objective on shares of Elanco Animal Health from $16.00 to $17.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $17.29.

Insider Activity at Elanco Animal Health

In other news, Director R David Hoover acquired 20,000 shares of the firm's stock in a transaction on Wednesday, March 6th. The shares were purchased at an average price of $16.14 per share, for a total transaction of $322,800.00. Following the completion of the transaction, the director now owns 185,000 shares of the company's stock, valued at $2,985,900. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.57% of the stock is currently owned by company insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.